For all press and media enquiries please contact mediarelations@chiesi.com
The pharmaceutical Group’s new head office, which will guide its growth and internationalisation strategies, will be located in Parma and will house around 540 people. People, innovation, sustainability: three words which sum up the philosophy behind this new project, developed on the basis of a new…
The Chiesi Group, represented by the CEO Ugo Di Francesco, took part at the French International Summit. Event wanted by the President of the French Republic Emmanuel Macron, who saw protagonists CEOs and Presidents of the world's largest multinational companies, members of the French Parliament,…
The 2017 edition of the EU Industrial R & D Investment Scoreboard of the European Commission places Chiesi Group at the top of the Italian pharmaceutical companies in terms of investments in Research and Development. Compared to the previous year, the growth of Chiesi Group's investments (12.6%) is…
The award is assigned to 10 affiliates of Chiesi Group. In 2018, the Group celebrates Top Employers for the 10th year running in Italy and for the 6th year running in Europe. The independent research by Top Employers Institute rewards the Company excellence in HR practices, thanks to the employee…
The TRIBUTE study showed superiority of Chiesi’s extrafine formulation triple combination, Trimbow ® (beclometasone/formoterol/glycopyrronium) over Ultibro ® Breezhaler ® (indacaterol/glycopyrronium) in terms of rate of moderate-to-severe exacerbations in patients affected by Chronic Obstructive…
Chiesi Farmaceutici Spa (“Chiesi”) acknowledges that uniQure biopharma B.V (uniQure), have taken the decision to withdraw the ongoing application for the Marketing Authorization Renewal of Glybera, for which Chiesi holds commercialization rights for Europe and other selected countries. This request…
Chiesi Group closes 2016 with a turnover of € 1.571 million, up 7.0% on 2015 (+9.6% at a constant exchange rate). The international footprint of the Group continues to grow: 83% of turnover comes from the non-Italian market. Significant growth in the European affiliates, which have now reached a…
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study. TRINITY is the first study to demonstrate the superiority of triple therapy with a fixed dose combination of an inhaled…
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps Chiesi Farmaceutici welcomes the recently published GOLD report but identifies three key elements in the treatment recommendations, which deserve thorough evaluation and further revision: Limited evidence base Misalignment with approved…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
